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Upon infection, CD8+ T cells undergo a stepwise pro-
cess of early activation, expansion, and differentia-
tion into effector cells. How these phases are
transcriptionally regulated is incompletely defined.
Here, we report that interferon regulatory factor 4
(IRF4), dispensable for early CD8+ T cell activation,
was vital for sustaining the expansion and effector
differentiation of CD8+ T cells. Mechanistically, IRF4
promoted the expression and function of Blimp1
and T-bet, two transcription factors required for
CD8+ T cell effector differentiation, and simulta-
neously repressed genes that mediate cell cycle
arrest and apoptosis. Selective ablation of Irf4 in pe-
ripheral CD8+ T cells impaired antiviral CD8+ T cell
responses, viral clearance, andCD8+ T cell-mediated
host recovery from influenza infection. IRF4 expres-
sion was regulated by T cell receptor (TCR) signaling
strength via mammalian target of rapamycin (mTOR).
Our data reveal that IRF4 translates differential
strength of TCR signaling into different quantitative
and qualitative CD8+ T cell responses.
INTRODUCTION
CD8+ T cells are an essential component of antiviral and anti-
tumor immunity (Zhang and Bevan, 2011). During an infection,
naive CD8+ T cells rapidly undergo three stepwise stages of re-
sponses (early activation, clonal expansion, and effector differ-
entiation) to generate a large number of antigen-specific effector
T cells for pathogen clearance. During this process, CD8+ T cells
acquire the ability to express cytolytic molecules such as gran-
zyme B (Gzmb) for direct cell killing and to produce effector
cytokines such as interferon gamma (IFN-g) for indirect activa-
tion of antiviral and antitumor responses. Signals derived from
antigen-presenting cells including peptide-major histocompati-
bility complex (MHC), costimulatory molecules, and inflamma-
tory cytokines ultimately control CD8+ T cell expansion andIeffector differentiation. In particular, in the past several years,
the strength (affinity) of T cell receptor (TCR) signaling has
been shown to be critical for determining the size and duration
of CD8+ T cell expansion and the functional differentiation of
CD8+ T cells (Denton et al., 2011; King et al., 2012; Vigano`
et al., 2012; Zehn et al., 2009). Currently, the underlying molecu-
lar mechanisms by which TCR signal strength influences the
expansion and differentiation of CD8+ T cells are not very well
understood.
The expansion and effector differentiation of CD8+ T cells are
also subject to the regulation of various transcription factors. The
transcription factor Id2 promotes the survival of activated CD8+
T cells and controls the expansion size of antigen-specific CD8+
effector T cells, whereas the transcription factors T-bet, Eomes,
Runx3, and Blimp1 are required for the expression of effector
molecules and thus are essential for the process of CD8+ T cell
effector differentiation (Kaech and Cui, 2012; Zhang and Bevan,
2011). Interferon regulatory factor 4 (IRF4) is a member of the IRF
family of transcription factors and has been shown to play critical
roles in orchestrating the effector differentiation of multiple line-
ages of CD4+ T helper (Th) cells (Xu et al., 2012). Recent reports
also have begun to shed light on the functions of IRF4 expression
in CD8+ T cells. In particular, IRF4 expression in the thymus has
been implicated in the development of CD122+ innate-like CD8+
T cells (Nayar et al., 2012). Furthermore, IRF4 is required for the
generation of interleukin-17 (IL-17)- or IL-9-producing CD8+
T cells in response to differential polarizing cytokines in vitro
(Huber et al., 2013; Visekruna et al., 2013). However, the role
of IRF4 in the development of conventional IFN-g-producing
effector CD8+ T cell responses in vivo is currently unknown.
In this report, by using an in vitro model of dendritic cells (DCs)
and CD8+ T cell coculture as well as an in vivo model of influenza
virus infection, we found that IRF4 was not required for the early
activation of CD8+ T cells but was critical for controlling the
expansion and effector differentiation of CD8+ T cells in response
to TCR signaling strength. We found that IRF4 repressed Bim
and CDK inhibitors to prolong the survival and proliferation of
activated CD8+ T cells. In addition, IRF4 promoted Blimp1 and
T-bet expression and sustained active Ifng and Gzmb pro-
moters, thereby enhancing effector differentiation of CD8+
T cells. We showed that selective ablation of IRF4 in peripheral
CD8+ T cells impaired antiviral CD8+ T cell responses, viralmmunity 39, 833–845, November 14, 2013 ª2013 Elsevier Inc. 833
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enza virus infection. These data reveal a critical role of IRF4 in
translating the strength of TCR signaling into the quantity and
quality of effector CD8+ T cell responses.
RESULTS
TCR Strength Determines IRF4 Expression during CD8+
T Cell Activation
IRF4 is required for the proper differentiation and function of reg-
ulatory T cells andmany effector Th cell subsets (Xu et al., 2012).
However, the role of IRF4 in antigen-specific CD8+ T cell re-
sponses remains unknown. We found that the Irf4 expression
was rapidly upregulated in vitro in polycolonal CD8+ T cells stim-
ulated with bone-marrow-derived DCs (BMDCs) and soluble
a-CD3 (Figures 1A and 1B). Moreover, TCR restimulation of acti-
vated CD8+ T cells could further increase Irf4 expression (Fig-
ure S1A available online). IRF4 also was highly expressed in vivo
by OT-I TCR-transgenic CD8+ T cells after influenza A/PR8-OVA
infection (Figure 1C). Furthermore, high-affinity OT-I TCR ligand
(SIINFEKL, N4 peptide) induced stronger and prolonged IRF4
expression compared to low-affinity altered peptide ligands (T4
peptide, SIITFEKL; Q4H7 peptide, SIIQFEHL) (Figure 1D; King
et al., 2012; Zehn et al., 2009), suggesting that IRF4 expression
in CD8+ T cells correlates with TCR signaling strength. Consis-
tent with this idea, IRF4 expression in activated CD8+ T cells
also was correlated with the dose of peptide used in the culture
(Figure S1B). We found that high TCR stimulation strength
induced higher activities of the kinasemammalian target of rapa-
mycin (mTOR) signaling and that rapamycin treatment impaired
IRF4 expression in polyclonal CD8+ T cells or OT-I cells stimu-
lated by N4 or T4 peptide (Figures 1E–1G and S1C). Together,
these data suggested that IRF4 expression in CD8+ T cells is
determined by the strength of TCR signaling in a manner relying
partially on differential mTOR signaling. Recently, IL-2 inducible
T cell kinase (ITK) has been shown to regulate IRF4 expression in
CD8+ T cells (Nayar et al., 2012). We found that an ITK inhibitor in
conjunction with rapamycin had synergistic effects in inhibiting
IRF4 expression (Figure S1D), suggesting that mTOR and ITK
signaling cooperatively regulate IRF4 expression during CD8+
T cell activation.
Selective IRF4 Ablation in CD8+ T Cells Impairs
the Magnitude of CD8+ T Cell Responses
IRF4 expression in the thymus has been shown to regulate the
development of innate-like CD8+ T cells (Nayar et al., 2012). To
bypass the effects of IRF4 deletion in thymic CD8+ T cells, we
crossed Irf4fl/fl mice to distal Lck-cre transgenic mice and gener-
ated peripheral T cell-specific conditional IRF4 mutant mice
(Irf4DT) (Prlic and Bevan, 2011). Control (Irf4fl/fl) and Irf4DT mice
were then infected with influenza and T cell responses were
examined. We found that at day 7 after infection, the total num-
ber of T cells, in particular CD8+ T cells, was dramatically dimin-
ished within the infected lung, where antigen-specific effector
T cells should be enriched (Figure S2A). We also examined anti-
gen-specific CD8+ T cell responses by staining the NP366 and
PA224 tetramers. We found that IRF4 deletion in T cells greatly
impaired the generation of influenza-specific CD8+ T cells in
the lung, draining mediastinal lymph nodes (MLNs), and spleen834 Immunity 39, 833–845, November 14, 2013 ª2013 Elsevier Inc.(Figure 2A), suggesting that IRF4 is vital for robust antiviral
CD8+ T cell responses during influenza infection.
To rule out the possibility that IRF4 expression in CD4+ T cells
may be responsible for the phenotype, we generated CD8+
T cell-specific IRF4 conditional mutant mice (Irf4DCD8) by
crossing Irf4fl/fl mice with Cd8a-cre transgenic mice (Maekawa
et al., 2008). By utilizing GFP expression after cre expression
as an indicator of excision (Klein et al., 2006), we confirmed
that the deletion of the Irf4 gene occurred specifically in periph-
eral CD8+ T cells and not in CD4+ T cells (Figure 2B). Further-
more, we found that cre-mediated Irf4 deletion did not occur in
the double-positive stage of thymocytes and occurred only
partially (30%) in single CD8+ thymocytes, suggesting that
Irf4 deletion in Irf4DCD8 mice is a feature of mature CD8+ T cells
(Figure S2B). We observed that splenic CD8+ T cells isolated
from Irf4DCD8 mice showed no signs of innate-like CD8+ T cells
(Figure S2C–S2E). Furthermore, spleen or LN CD8a+ DCs from
Irf4DCD8mice, which were required for the optimal CD8+ T cell re-
sponses after viral infection (Belz et al., 2004), were cre recombi-
nase negative and expressed the same amount of IRF4 as did
CD8a+ DCs from control mice (Figures S2F and S2G). Thus,
this CD8+ T cell-specific Irf4 mutant mouse strain allows us to
specifically examine IRF4 function in peripheral CD8+ T cell
responses after infection.
We infected Irf4DCD8 mice with influenza and examined CD8+
T cell responses. We found that Irf4DCD8 mice exhibited dimin-
ished CD8+ but not CD4+ T cell lung infiltration at days 7 and 9
after infection (Figures S2H and S2I). Irf4 deletion in CD8+
T cells resulted in diminished percentages (Figures 2C and 2D)
and numbers (Figure 2E) of influenza-specific NP366
+ and
PA244
+ T cells in the lung, MLN, and spleen at days 7 and 9 after
infection. Irf4DCD8mice also exhibited diminished percentages of
antigen-specific T cells in the memory phase (day 42) after virus
was cleared (Figure S2J). These data together suggested that
IRF4 expression in mature CD8+ T cells is essential for the devel-
opment of robust antiviral CD8+ T cells during influenza infection.
IRF4 Sustains CD8+ T Cell Expansion
We next used an in vitro DC and CD8+ T cell coculture system to
examine the underlying mechanisms by which IRF4 regulates
CD8+ T cell responses. To this end, control or IRF4-deficient
CD8+ T cells were stimulated with DC plus soluble a-CD3 and
T cell activation and expansion were followed. We found that
IRF4-deficient CD8+ T cells were able to acutely upregulate
CD25 (IL-2Ra) and CD69, expressed similar IL-2Rb and
IL-2Rg, and produced comparable IL-2 at the early time point
of T cell activation (day 1) (Figures 3A, 3B, S3A, and S3B). How-
ever, IRF4-deficient CD8+ T cells failed to expand and accumu-
late compared with control CD8+ T cells (Figure 3C). Further-
more, in correlation with high and prolonged expression of
IRF4, CD8+ T cells stimulated with strong TCR signaling induced
greater and prolonged expansion of CD8+ T cells after stimula-
tion (Figures 3D and S3C). Thus, these data suggested that
IRF4 is essential for the expansion of CD8+ T cells. The failed
expansion of IRF4-deficient T cells was not due to the difference
of IL-21 expression (a cytokine controlled by IRF4 in Th cells)
(Figure S3D; Huber et al., 2008). Furthermore, provision of
IL-21 or provision of human IL-2 in the presence of mouse
IL-2-neutralizing Ab (so we can accurately control the amount
Figure 1. mTOR Signaling Regulates IRF4 Expression in CD8+ T Cells
(A and B) IRF4 mRNA (A) and protein expression (B) in polyclonal CD8+ T cells after activation in vitro.
(C) OT-I T cells were transferred in Thy1 mismatched mice and then the mice were infected with PR8-OVA. IRF4 expression in OT-I T cells in draining MLN at day
3.5 p.i.
(D) IRF4 expression in OT-I T cells stimulated with N4, T4, or Q4H7 peptide.
(E) mTOR signaling in OT-I cells as indicated by S6 phosphorylation after 24 hr N4, T4, or Q4H7 peptide stimulation.
(F) IRF4 expression in polyclonal CD8+ T cells after vehicle (DMSO) or rapamycin (Rapa) treatment.
(G) IRF4 MFI of OT-I cells stimulated with N4 or T4 in the presence of DMSO or Rapa at 24 hr after stimulation.
Data are representative of two to four independent experiments. See also Figure S1.
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IRF4 Sustains CD8+ T Cell Responsesof bioactive IL-2) did not reverse the expansion defects of IRF4-
deficient CD8+ T cells (Figures S3E and S3F), formally ruling out
the possibility that the failed expansion of IRF4-deficient CD8+
T cells was due to the lack of endogenous IL-2 or IL-21
production.
The expansion of CD8+ T cells is controlled by cell proliferation
and death (Ream et al., 2010). IRF4-deficient CD8+ T cells ex-
hibited enhanced cell death as evidenced both by increased pro-
portions of 7-AAD+ dead cells in the culture (Figures 3E and 3F)
and by enhanced percentages of active caspase-3+ (earlyIapoptosis marker) in the gated live cells (Figure 3G). Further-
more, consistent with their IRF4 expression, T cells stimulated
with weak TCR signals showed enhanced cell death after activa-
tion (Figure S3G). These data suggested that IRF4 expression in
CD8+ T cells is critical for the survival of the activated CD8+
T cells. We next examined the proliferation of IRF4-deficient
CD8+ T cells after activation. We found that IRF4-deficient
CD8+ T cells were able to initiate several rounds of division after
activation (Figure 3H), which is consistent with the idea that IRF4
is not required for the early activation of CD8+ T cells. However,mmunity 39, 833–845, November 14, 2013 ª2013 Elsevier Inc. 835
Figure 2. IRF4 Ablation in CD8+ T Cells
Impairs the Magnitude of CD8+ T Cell
Responses In Vivo
(A) Irf4DT mice were infected with influenza. Influ-
enza-specific NP366 and PA224 tetramer staining in
lung, MLN, and spleen CD8+ T cells at day 7 p.i.
(B) GFP expression spleen CD8+ and CD4+ T cells
in naive Irf4DT and Irf4DCD8 mice.
(C–E) Irf4DCD8 mice were infected with influenza.
Representative plots of NP366 and PA224 tetramer
staining (C), percent of NP366 and PA224 tetramer
+
cells in lung, MLN, and spleen CD8+ T cells (D),
and the numbers of NP366 and PA224 tetramer
+
CD8+ T cells in lung, MLN, and spleen (E) at days 7
and 9 p.i. Data are mean ± SEM.
Data are representative of at least three indepen-
dent experiments (n = 3–4 mice per group per
experiment). *p < 0.05. See also Figure S2.
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IRF4 Sustains CD8+ T Cell ResponsesIRF4-deficient CD8+ T cells failed to efficiently sustain their pro-
liferation (Figure 3H). Furthermore, CD8+ T cells stimulated with
weak TCR signal also showed diminished cell proliferation after
activation (Figure S3H). Thus, IRF4 is essential to sustain the
expansion of CD8+ T cells after activation by promoting both
the proliferation and survival of activated CD8+ T cells.
BATF, a basic leucine zipper transcription factor, was recently
found to be an important binding partner of IRF4 and is required
for many aspects of IRF4 function in CD4+ T cells (Ciofani et al.,
2012; Li et al., 2012). However, although BATF-deficient CD8+836 Immunity 39, 833–845, November 14, 2013 ª2013 Elsevier Inc.T cells exhibited enhanced active cas-
pase-3 and cell death after activation
(Figures 3I and S3I), the cells proliferated
comparably to WT CD8+ T cells (Fig-
ure 3J). This indicates that BATF-defi-
cient T cells show only a partial expansion
defect as compared to IRF4-deficient
CD8+ T cells (Figure S3J) and suggests
that IRF4 regulates the expansion of
CD8+ T cells by BATF-dependent and -in-
dependent mechanisms.
We next activatedWT CD8+ T cells and
transduced them with IRF4-expressing
retroviruses. The growth of virus-trans-
duced cells (human (h)-CD4+) was moni-
tored between days 1 and 3 after trans-
duction (days 2 and 4 after the culture).
We predicted that if the expression of
IRF4 provided selective advantage, the
proportion of hCD4+ cells within the live
gate would increase. Consistent with
this expectation, although the percent-
ages of hCD4+ cells remained constant
between day 2 and day 4 in the control
group, the percentages of hCD4+ cells
dramatically increased in the group of
CD8+ T cells transduced with IRF4-ex-
pressing retrovirus (Figures 3K and 3L).
The increased percentages of IRF4-
transduced cells were associated withincreased proliferation of transduced cells (Figure S3K).
Together, these data suggest that ectopic expression of IRF4
promotes polyclonal CD8+ T cell expansion after activation.
We also expressed IRF4 ectopically in OT-I T cells and observed
T cell expansion after high- or low-affinity peptide ligand stimu-
lation. We found that IRF4 had a moderate effect in promoting
the expansion of OT-I T cells stimulated by high-affinity peptide
ligand N4, presumably as a result of the high endogenous
expression of IRF4 (Figures 3M and 1D). In contrast, ectopic
expression of IRF4 strongly promoted the expansion of OT-I
Immunity
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Q4H7 (Figures 3M). The enhanced expansion of IRF4 in trans-
duced T cells also was associated with the enhanced prolifera-
tion (Figure S3L). Taken together, these data suggest that a
high IRF4 expression is critical for sustaining the expansion of
CD8+ T cells after activation.
IRF4 Sustains CD8+ TCell Expansion byRepressingCDK
Inhibitors and Bim
We next sought to examine the underlying molecular mecha-
nisms by which IRF4 sustains the expansion of CD8+ T cells.
Myc and Id2 were previously shown to regulate CD4+ and
CD8+ T cell expansion, respectively (Cannarile et al., 2006;
Guy et al., 2013). However, IRF4-deficient CD8+ T cells ex-
pressed comparable Myc and Id2 as did control CD8+
T cells, suggesting that IRF4 regulates CD8+ T cell expansion
independently of Myc and Id2 (Figures S4A and S4B). After
activation, IRF4-deficient CD8+ T cells exhibited enhanced
expression of multiple cyclin-dependent kinase (CDK) inhibi-
tors, including Cdkn2a, Cdkn1a, and Cdkn1c (Figure 4A; Cice-
nas and Valius, 2011). Consistent with their ability to proliferate
normally, BATF-deficient CD8+ T cells expressed CDK inhibi-
tors similar to WT CD8+ T cells (Figure 4B). IRF4 can act as
either transcription activator or transcription repressor (Biswas
et al., 2010). We hypothesized that perhaps IRF4 binds directly
to DNA to repress the expression of these Cdkn genes. In sup-
port of this idea, the Cdkn2a locus contains a potential IRF4
binding site (Figure S4C) and IRF4 was shown to bind directly
to the Cdkn2a locus by a ChIP assay (Figure 4C). Collectively,
these data indicate that IRF4 sustains CD8+ T cell proliferation
by repressing the production of CDK inhibitors. The underlying
mechanisms by which IRF4 controls the survival of activated
CD8+ T cells also was investigated. IRF4-deficient CD8+
T cells expressed equivalent antiapoptotic genes (Figures
S4D and S4E). However, IRF4-deficient CD8+ T cells ex-
pressed increased proapoptotic gene Bcl2l11 (encodes Bim)
after activation (Figures 4D and 4E). Similarly, BATF-deficient
CD8+ T cells expressed higher Bim (Figures 4F and 4G)
than did WT CD8+ T cells. Once again, IRF4 bound directly
to the Bcl2l11 locus (Figures 4H and S4F). Thus, IRF4 pro-
motes the expansion of CD8+ T cells by targeting its transcrip-
tional repression activity to genes encoding CDK inhibitors
and Bim.
IRF4 Is Required for CD8+ T Cell Proliferation
and Survival In Vivo
We next examined whether IRF4 is required for the optimal pro-
liferation and survival of CD8+ T cells in vivo. To do so, control
or Irf4DCD8 mice were infected with influenza and CD8+ T cell
proliferation was measured on day 7 by BrdU incorporation.
Results showed that IRF4-deficient CD8+ T cells incorporated
dramatically less BrdU in the lung, indicating that IRF4 expres-
sion is vital for the proliferation of CD8+ T cells in vivo (Fig-
ure 5A). Furthermore, IRF4-deficient CD8+ T cells in the lung
expressed higher active caspase 3 and Bim (Figures 5B and
5C). These data are consistent with our in vitro observations
and suggest that IRF4 expression is required for the prolifera-
tion and survival of antiviral CD8+ T cells during influenza
infection.IIRF4 Sustains CD8+ T Cell Effector Differentiation
In conjunction with rapid expansion, activated CD8+ T cells un-
dergo an effector differentiation process to gain the ability to
rapidly produce both the cytotoxic molecules and effector cyto-
kines required for the clearance of intracellular pathogens. IRF4-
deficient CD8+ T cells were able to upregulate GzmbmRNA and
protein early after stimulation (day 1 after activation) (Figures 6A
and 6B) but failed to sustain the expression of this gene (Figures
6A and 6B). Likewise, IRF4-deficient CD8+ T cells were able to
upregulate IFN-g production early after stimulation but failed to
sustain the production of IFN-g at later times during activation
(Figures 6C and S5A). T cells stimulated with weak TCR signals
also failed to sustain Gzmb and IFN-g (Figures S5B and S5C).
These data suggest that IRF4 sustains the effector differentiation
of CD8+ T cells after in vitro activation.
We next wondered whether the decreased maintenance of
effector molecules was merely due to the selective death of
effector CD8+ T cells as indicated by the fact that IRF4-deficient
CD8+ T cells showed enhanced cellular apoptosis. The survival
of effector CD8+ T cells is controlled by the balanced expression
of antiapoptotic Bcl2 and proapoptotic Bim (Kurtulus et al.,
2011). Therefore, it is possible that enhanced expression of
Bcl2 could counterbalance the effects of Bim expression to pre-
vent the death of IRF4-deficient T cells. To test this, WT or IRF4-
deficient CD8+ T cells were transduced with a Bcl2-expressing
retrovirus. Ectopic expression of Bcl2 decreased cellular
apoptosis of IRF4-deficient CD8+ T cells (Figure S5D). However,
ectopic expression of Bcl2 failed to rescue IFN-g production by
IRF4-deficient CD8+ T cells (Figure 5D), suggesting that the abil-
ity of IRF4 to sustain CD8+ T cell effector differentiation is not due
to the selective apoptosis of effector molecule-expressing cells.
We next investigated how IRF4might be functioning to sustain
the effector differentiation of CD8+ T cells. After T cell activation,
IRF4 was required for the expression of Prdm1 (Figure 6E), a crit-
ical gene whose product (Blimp1) promotes the expression of
cytolytic molecules (Shin et al., 2009). IRF4 was able to bind
directly to multiple DNA sites within the Prdm1 locus in CD8+
T cells (Figure 6F), suggesting that IRF4 promotes Prdm1 tran-
scription. The T-box transcription factors T-bet and Eomes
play important roles in the effector differentiation of CD8+
T cells (Intlekofer et al., 2008; Kaech and Cui, 2012; Zhang and
Bevan, 2011). For these genes, IRF4 was important for the
optimal expression of T-bet (Tbx21), but not Eomes (Eomes), in
CD8+ T cells (Figures 6G, 6H, and S5E). Given that IRF4 only
partially controlled T-bet expression in CD8+ T cells, we next
examined whether IRF4 could regulate T-bet function in CD8+
T cells. To this end, we observed diminished binding by T-bet
to the Gzmb and Ifng promoters in IRF4-deficient CD8+ T cells
(Figure 6I), suggesting that IRF4 is required for the function of
T-bet. The effector differentiation of CD8+ T cells is accompanied
by intensive epigenetic chromatin modifications in the promoter
regions of effector molecule genes (Olson et al., 2010). These
active chromatinmodifications are required for effector molecule
expression and lineage specification of effector CD8+ T cells.
IRF4-deficient CD8+ T cells exhibited diminished active histone
modifications, the trimethylation of H3K4, and the acetylation
of H3K27 in both Gzmb and Ifng promoter regions (Figures 6J
and 6K). In addition, IRF4-deficient CD8+ T cells exhibited dimin-
ishedHif1a (Figure S5F), a transcription factor that was shown tommunity 39, 833–845, November 14, 2013 ª2013 Elsevier Inc. 837
Figure 3. IRF4 Is Dispensable for Early T Cell Activation but Vital for CD8+ T Cell Expansion
(A) CD25 and CD69 expression of control or IRF4-deficient polycolonal CD8+ T cells (day 1 after activation).
(B) IL-2 in the cultured medium of control or IRF4-deficient polyclonal CD8+ T cells (day 1 after activation). Data are mean ± SD.
(C) Cell numbers of control or IRF4-deficient polyclonal CD8+ T cells after stimulation. Data are mean ± SD.
(D) Cell numbers of OT-I T cells stimulated with N4, T4, or Q4H7 peptide. Data are mean ± SD.
(legend continued on next page)
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IRF4 Sustains CD8+ T Cell Responsespromote the effector differentiation of CD8+ T cells (Finlay et al.,
2012). Taken together, these data suggested that IRF4 sustains
the effector differentiation of activated CD8+ T cells by control-
ling multiple checkpoints of effector differentiation including
the expression Prdm1, Tbx21, and Hif1a, the binding of T-bet
to its targets, and the active modifications of histones in the pro-
moter regions of effector molecules.
We also transduced control or IRF4-expressing virus into
CD8+ T cells and examined CD8+ T cell effector molecule
expression. We found that IRF4 modestly promoted Gzmb
expression (Figure S5G) but dramatically enhanced IFN-g pro-
duction by activated CD8+ T cells (Figure 6L). Furthermore,
ectopic expression of IRF4 also promoted IFN-g production by
CD8+ T cells stimulated with low-affinity peptide ligands (Fig-
ure 6M). Taken together, these data suggested that IRF4 expres-
sion in CD8+ T cells is essential for sustaining the effector
differentiation of CD8+ T cells after activation.
IRF4 Is Required for CD8+ T Cell Effector Differentiation
and Function In Vivo
We next examined whether IRF4 is required for the effector dif-
ferentiation of CD8+ T cells in vivo. Irf4DCD8 mice were infected
with influenza and Gzmb expression in CD8+ T cells was exam-
ined at days 7 and 9 p.i. At both time points, IRF4 deficiency
impaired Gzmb expression in both total and influenza-specific
PA224-tetramer
+ CD8+ T cells (Figures 7A, 7B, S6A, and S6B).
IRF4 deficiency in CD8+ T cells also diminished the percentages
of IFN-g+ cells and, importantly, the per cell expression of IFN-g
(Figures 7C, 7D, S6C, and S6D). Additionally, IRF4 deficiency in
CD8+ T cells resulted in diminished airway IFN-g in vivo (Fig-
ure 7E). The diminished Gzmb and IFN-g production in lung
IRF4-deficient CD8+ T cells was associated with their decreased
expression of Tbx21, Prdm1, and CDK inhibitors (Figure S6E).
Taken together, these data suggested that IRF4 is required for
CD8+ T cell effector differentiation in vivo.
Given that IRF4 is both important for sustaining the expansion
and the effector differentiation of CD8+ T cells, we sought to
investigate whether IRF4 is required for host antiviral responses
in vivo. We found that Irf4DCD8 mice exhibited enhanced infec-
tious virus titers in the airway and increased viral gene expres-
sion in the infected lungs at day 9 after infection (Figures 7F
and 7G), suggesting that IRF4 deficiency in CD8+ T cells
impaired host antiviral responses. During influenza infection,
CD4+ T cells, CD8+ T cells, and B cells play compensatory and
redundant roles to eliminate virus and promote host recovery
(Braciale et al., 2012; Brown et al., 2004). To examine the effects
of IRF4 expression in CD8+ T cells in host recovery from influenza(E) 7-AAD staining of control or IRF4-deficient polyclonal CD8+ T cells in the cult
(F) The percentages of 7-AAD+ cells in control or IRF4-deficient polyclonal CD8+
(G) The percentages of active caspase 3+ cells in the live control or IRF4-deficie
(H) Proliferation of control or IRF4-deficient polyclonal CD8+ T cells.
(I) The percentages of active caspase 3+ cells in the live WT or BATF-deficient p
(J) Proliferation of WT or BATF-deficient polyclonal CD8+ T cells.
(K and L) WT CD8+ T cells were left untransduced or transduced with control or IRF
cells in live CD8+ T cells at day 2 and day 4 after activation.
(M) OT-I T cells were stimulated with N4, T4, or Q4H7 peptide and transduced wi
OT-I T cells were monitored.
Data are representative of two to four independent experiments except in (F) and
also Figure S3.
Iinfection, we infected control and Irf4DCD8 mice with influenza
and then depleted CD4+ T cells. We thenmonitored host survival
after influenza infection. We found that IRF4 deficiency in CD8+
T cells significantly enhanced host mortality after influenza virus
infection (Figure 7H). Taken together, these data have estab-
lished that IRF4 expression in CD8+ T cells is critical for the anti-
viral activities of CD8+ T cells during acute respiratory viral
infection.
DISCUSSION
The transcriptional programs regulating effector CD8+ T cell re-
sponses are incompletely defined. In this report, we have identi-
fied a prominent role of IRF4 in regulating robust development of
effector CD8+ T cells during acute respiratory virus infection.
IRF4 exerts its effects by sustaining both expansion and effector
differentiation of activated CD8+ T cells. Previously, several tran-
scription factors have been identified to regulate either the
expansion or effector differentiation of primary CD8+ T cell re-
sponses. For example, Id2 enhances the expansion of effector
CD8+ T cells by maintaining the survival of effector CD8+
T cells (Cannarile et al., 2006), whereas Runx3, T-bet, Blimp1,
and Eomes control the effector differentiation of CD8+ T cells
but have little effect on the expansion of effector CD8+ T cells
(Kaech and Cui, 2012; Zhang and Bevan, 2011). Thus, the ability
of IRF4 to regulate both the expansion and effector differentia-
tion of CD8+ T cells is distinct from previously described factors.
We believe that IRF4 regulates the expansion of CD8+ T cells
through Id2-independent mechanisms as IRF4 directly re-
presses Bcl2l11 and CDK inhibitors, thus promoting survival
and cell cycle progression. In contrast, IRF4 sustains the effector
differentiation of CD8+ T cells indirectly through regulating the
expression and function of Tbx21 and Prdm1. Hence, IRF4-defi-
cient CD8+ T cells show impaired expression of effector mole-
cules such as IFN-g and Gzmb.
The proper expansion and effector differentiation of CD8+
T cells can be influenced by a variety of signals. However, the
strength and quality of TCR signaling appears to play a critical
role in the process. Triggering of naive T cells with peptide epi-
topes with low functional affinity for the TCR often resulted in
the early or premature induction of apoptosis in effector cells
because of an imbalance in the expression of pro- and antiapop-
totic factors (Hommel and Hodgkin, 2007; Ream et al., 2010).
In vivo, very weak TCR-ligand interactions are sufficient to acti-
vate naive T cells but resulted in a lower magnitude of expansion
and earlier onset of T cell contraction compared to strong TCR-
ligand interactions (Denton et al., 2011; Zehn et al., 2009). Moreure.
T cells in the culture (day 2 after activation).
nt polyclonal CD8+ T cells (day 2 after activation).
olyclonal CD8+ T cells (day 2 after activation).
4-expressing retroviruses. hCD4 staining (K) and the percentages (L) of hCD4+
th control or IRF4-expressing retrovirus. The percentages of hCD4+ cells in live
(L), wherein data are pooled from four independent experiments. *p < 0.05. See
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Figure 4. IRF4 Regulates CD8+ T Cell
Expansion by Repressing CDK Inhibitors
and Bim
(A) Expression of various CDK inhibitors in control
or IRF4-deficient polyclonal CD8+ T cells.
(B) Expression of various CDK inhibitors in WT or
BATF-deficient polyclonal CD8+ T cells.
(C) IRF4 binding to Cdkn2a locus in control or
IRF4-deficient polyclonal CD8+ T cells was deter-
mined by ChIP assay (day 2 after activation). Data
are mean ± SD.
(D and E) Bim mRNA (Bcl2l11) (D) and protein (E)
expression in control or IRF4-deficient polyclonal
CD8+ T cells at indicated times (D) or day 2 (E) after
activation.
(F and G) Bim mRNA (Bcl2l11) (F) and protein (G)
expression in control or BATF-deficient polyclonal
CD8+ T cells at indicated times (F) or day 2 (G) after
activation.
(H) IRF4 binding to Bcl2l11 locus in control or
IRF4-deficient polyclonal CD8+ T cells was deter-
mined by ChIP (day 2 after activation). Data are
mean ± SD.
Data are representative of three to four indepen-
dent experiments. See also Figure S4.
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IRF4 Sustains CD8+ T Cell Responsesrecently, the strength of the TCR ligand was also shown to influ-
ence full effector differentiation, tissue infiltration, and the path-
ological activities of CD8+ T cells in vivo (King et al., 2012).
Currently, the molecular mechanisms underlying the differential
responses of CD8+ T cells stimulated with high and low affinity
of TCR ligands are unknown. We found that IRF4 expression
was highly induced and sustained with strong TCR stimulation
and that IRF4 deficiency in CD8+ T cells resulted in lower magni-
tude, earlier contraction, and diminished effector molecule
expression in vitro and in vivo. Moreover, ectopic expression
of IRF4 enhanced CD8+ T cell expansion and effector cytokine
production in CD8+ T cells stimulated with low strength of TCR
signaling. Thus, we have identified IRF4 as a potential important840 Immunity 39, 833–845, November 14, 2013 ª2013 Elsevier Inc.downstream transcription factor that
translates the strength of TCR signaling
into the quantity and quality of CD8+
T cell responses. It will be of interest in
the future to test whether IRF4 is capable
of rescuing the curtailed expansion and
effector differentiation of CD8+ T cells in
response to low-affinity TCR signaling
strength in vivo during infection and/or
vaccination (Denton et al., 2011; King
et al., 2012; Vigano` et al., 2012; Zehn
et al., 2009). Such information would be
useful for designing modalities to manip-
ulate IRF4 expression in T cells to
promote effective cellular immunity to im-
munogens that typically induce weak
CD8+ T cell responses.
Our studies have shown that the
magnitude of mTOR signaling down-
stream of the different strength of TCR
stimulation regulated IRF4 expression inCD8+ T cells. Interestingly, IRF4 expression in CD8+ T cells
also was shown to be dependent on the function of ITK signaling
(Nayar et al., 2012). We found here that rapamycin and ITK inhib-
itors cooperatively inhibited IRF4 expression, suggesting that
ITK and mTOR signaling may function in parallel pathways to
promote IRF4 expression in CD8+ T cells. It is currently unclear
the exact mechanism by which mTOR controls IRF4 expression.
mTOR may promote IRF4 expression through its effects on
protein translation. Alternatively, mTOR could increase IRF4
transcription by its effects on downstream transcription factors
(Laplante and Sabatini, 2013). In this regard, NF-kB activity
is subject to mTOR regulation and Rel has been shown to
be an important transcription factor for IRF4 expression in
Figure 5. Selective Ablation of IRF4 in CD8+ T Cells Impairs CD8+
T Cell Proliferation and Survival In Vivo
Control or Irf4DCD8 mice were infected with influenza and injected with BrdU at
day 7 p.i.
(A) The percentages of BrdU+ cells in lung orMLN PA224 tetramer
+ T cells. Data
are mean ± SEM.
(B) The percentages of active caspase 3+ cells in lung or MLN PA224 tetramer
+
T cells. Data are mean ± SEM.
(C) Bim expression in lung or MLN PA224 tetramer
+ T cells.
Data are representative of three independent experiments (n = 3–4 mice per
group per experiment). *p < 0.05.
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IRF4 Sustains CD8+ T Cell Responseslymphocytes (Dan et al., 2008; Grumont and Gerondakis, 2000;
Hou et al., 2012). Further studies are needed to clarify these pos-
sibilities. Notably, mTOR signaling plays important roles in regu-
lating many aspects of effector CD8+ T cell responses including
proliferation, survival, and differentiation (Rao et al., 2010a,
2010b). Many of the effects of mTOR in the regulation of CD8+
T cell responses may be mediated through its role in promoting
IRF4 expression. For example, mTOR inhibition increases CDK
inhibitor function, impairs Blimp1 and T-bet expression, and en-
hances Eomes expression during primary effector T cell re-
sponses (Rao et al., 2010a, 2010b), similar to effects observed
in IRF4-deficient CD8+ T cells. Recently, HIF transcription factors
have been identified to be downstream of mTOR and to regulate
the effector differentiation of CD8+ T cells in response to IL-2
treatment (Finlay et al., 2012). We found that Hif1a gene expres-
sion was diminished in IRF4-deficient CD8+ T cells at day 3 after
activation, suggesting that IRF4 may also regulate the HIF
pathway to sustain effector differentiation and/or cellular meta-
bolism (Finlay et al., 2012). However, because HIF-1a protein
expression is tightly subject to posttranscriptional regulation by
oxygen concentrations in the cells, further studies are warranted
to define the exact relationship of IRF4 and HIF transcription fac-
tors in CD8+ T cell differentiation. Furthermore, because TCR
downstream signaling is often modulated by positive and nega-
tive signals derived from various costimulatory molecules andIcytokines, future studies should examine those signals and their
influence on IRF4 expression. Total IRF4 deficiency as well as
IRF4 conditional deletion in the double-positive stage of thymic
development (Cd4-cre-mediated deletion) lead to the develop-
ment of innate-like CD8+ T cells with a memory phenotype
(Nayar et al., 2012). In contrast, by using a mouse model condi-
tionally deleting IRF4 in a late stage of CD8+ T cells, we found
little evidence of the development of innate-like T cells, suggest-
ing that IRF4 expression in the double-positive stage of thymic
T cell development is responsible for the generation of innate-
like CD8+ T cells. Alternatively, the intrinsic deletion of IRF4 in
CD8+ T cells may be not sufficient to drive the development of
innate-like CD8+ T cells, because both CD8+ T cell-intrinsic
and -extrinsic signals were identified for the development of
innate-like CD8+ T cells (Nayar et al., 2012).
In conclusion, we have identified here that IRF4 is vital for the
development of effective cytotoxic T cell responses during viral
infection. IRF4 is also required for the differentiation of multiple
CD4+ Th cell lineages including Tfh cells, which promote the for-
mation of germinal centers for the production of high-affinity
neutralizing Abs (Crotty, 2011). Interestingly, high-affinity TCR
interaction and high-dose antigen stimulation preferentially
induce Tfh cell differentiation (Bollig et al., 2012; Fazilleau
et al., 2009). It is thus tempting to speculate that high strength
of TCR signaling controls IRF4 expression in CD4+ T cells and
subsequently facilitates IL-21 and Bcl6 expression for Tfh cell
differentiation in vivo. Future studies are needed to examine
these possibilities. Nevertheless, previous reports of the impor-
tance of IRF4 in Tfh and plasma cell differentiation (Bollig et al.,
2012; Klein et al., 2006; Kwon et al., 2009; Sciammas et al.,
2006) coupled with the data we present here on the role of
IRF4 in CD8+ T cell responses highlight the critical function of
IRF4 in the development of both humoral and cellular immunity
against infection or after immunization. We conclude that selec-
tive manipulation of IRF4 expression may serve as a potential
strategy to boost both humoral and cellular immunity during
vaccination, especially in those (e.g., infants and the elderly)
who respond poorly to vaccines.
EXPERIMENTAL PROCEDURES
Mouse and Infection
WTC57BL/6micewere purchased from the Jackson Laboratory. OT-I,Batf/
mice were bred in house. Irf4DT mice were generated by crossing Irf4fl/fl mice
with mice harboring distal Lck-cre transgenic mice (Wang et al., 2001). Irf4DCD8
mice were generated by crossing Irf4fl/fl mice with mice harboring Cd8a-cre
transgenic mice (Maekawa et al., 2008). All mice were housed in a specific-
pathogen-free environment and all animal experiments were performed in
accordance with protocols approved by the Indiana University Institutional
Animal Care and Use Committee. Influenza A/PR8/34 (200 pfu/mouse) and re-
combinant PR8-OVA (2,000 pfu/mouse) infection were performed as
described before (Sun et al., 2009). CD4+ T cell depletion was achieved by
the i.p. injection of GK1.5 Ab (1 mg/mouse) at day 3 p.i.
Quantitative RT-PCR
mRNA from cultured cells, in vivo purified CD8+ T cells, or lung homogenates
as indicated in the text was isolated with RNeasy kit (QIAGEN) and treated with
DNase I (Invitrogen). Random primers (Invitrogen) and Superscript II (Invitro-
gen) were used to synthesize first-strand cDNAs from equivalent amounts of
RNA from each sample. RT-PCR was performed with SYBR Green PCR
Master Mix (Applied Biosystems). Data were generated with the comparative
threshold cycle (Delta CT) method by normalizing to hypoxanthinemmunity 39, 833–845, November 14, 2013 ª2013 Elsevier Inc. 841
(legend on next page)
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Figure 7. Selective Ablation of IRF4 in CD8+
TCells Impairs CD8+ TCell Effector Differen-
tiation and Function In Vivo
Control or Irf4DCD8 mice were infected with
influenza.
(A and B) Gzmb expression (A) and MFI (B) in total
or PA224 tetramer
+ T cells at day 7 p.i.
(C and D) IFN-g production (C) and MFI (D) of day 7
CD8+ T cells after stimulation with influenza-in-
fected BMDCs.
(E) IFN-g in the BAL at day 7 p.i.
(F) Influenza virus titers in the BAL at day 9 p.i.
(G) Influenza virus gene (PA and M2) expression in
the lung at day 9 p.i.
(H) The survival of infected control or Irf4DCD8 mice
that were depleted with CD4+ T cells.
(A–E, G) Data are representative of three indepen-
dent experiments (n = 3–4 mice per group per
experiment).
(F and H) Data are pooled from total of three
independent experiments.
Data aremean±SEM. *p<0.05.SeealsoFigureS6.
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IRF4 Sustains CD8+ T Cell Responsesphosphoribosyltransferase (HPRT). Sequences of primers used in the studies
are available on request.
DC and T Cell Coculture
BMDCs were generated as described (Sun et al., 2011). CD8+ T cells were iso-
lated from spleen and lymph nodes of indicated mice through MACS-beads
(Miltenyi Biotech). Then, we mixed BMDCs with CD8+ T cells at the ratio of 1
DC:10 T cells in round-bottom 96 wells (5 3 104 T cells/well) in the presence
of 0.1 mg/ml soluble a-CD3. CD8+ T cells from OT-I mice were isolated and
cultured with N4, T4, or Q4H7 peptide (4 ng/ml or indicated concentration in
the text). In some experiments, hIL-2 (used as indicated U/ml in the text),Figure 6. IRF4 Sustains CD8+ T Cell Effector Differentiation
(A and B) Gzmb mRNA (A) and protein (B) expression in control or IRF4-deficient polyclonal CD8+ T cells.
(C) IFN-g production in control or IRF4-deficient polyclonal CD8+ T cells after PMA and ionomycin stimulati
(D) IFN-g production inMIT orMIT-Bcl2 retrovirus-transduced control or IRF4-deficient polyclonal CD8+ T cell
activation.
(E) Blimp1 mRNA (Prdm1) expression in control or IRF4-deficient polyclonal CD8+ T cells.
(F) IRF4 binding to Prdm1 promoter, CNS9, and 3-prime loci in control or IRF4-deficient polyclonal CD8+ T ce
Data are mean ± SD.
(G and H) T-bet mRNA (Tbx21) (G) and protein (H) expression in control or IRF4-deficient polyclonal CD8+ T
(I) T-bet binding to Gzmb and Ifng promoters in control or IRF4-deficient polyclonal CD8+ T cells was determi
mean ± SD.
(J and K) H3K27 acetylation and H3K4 methylation in Ifng (J) andGzmb (K) promoter regions in control or IRF4
by ChIP (day 2 after activation). Data are mean ± SD.
(L) IFN-g production by control or IRF4-expressing retrovirus-transduced WT polyclonal CD8+ T cells aft
activation (3 days after transduction).
(M) OT-I T cells were stimulated with N4, T4, or Q4H7 peptide and transduced with control or IRF4-expressing
after PMA and ionomycin stimulation at day 4 after activation (3 days after transduction) is depicted.
Data are representative of two to four independent experiments. See also Figure S5.
Immunity 39, 833–845, Nanti-mIL-2 (JES6-1A12, 20 mg/ml), and IL-21
(20 ng/ml) were used in the culture. Rapamycin
(100nM)andBMS-509744 (ITK inhibitor, 1mM) (Milli-
pore) were used to block mTOR and ITK signaling,
respectively. In some experiments, T cells were
labeled with eFluor670 (eBioscience) or CFSE (Invi-
trogen) according to manufacturer’s protocols.
Chromatin Immunoprecipitation
ChIP assay was performed as described (Ahyi
et al., 2009). In brief, 10 3 106 activated wild-typeor IRF4-deficient CD8+ T cells were cross-linked for 10 min with 1% formalde-
hyde and lysed by sonication. Cross-linked cells were precleared with salmon
sperm DNA, bovine serum albumin, and Protein A agarose (T-bet ChIP) or Pro-
tein G agarose (IRF4 ChIP) bead slurry (50%). Cell extracts were incubated
with antibodies to rabbit T-bet H-210, goat polyclonal IRF4 M-17 (Santa
Cruz), H3K27ac (Millipore), H3K4me3 (Abcam), normal goat IgG (Santa
Cruz), or normal rabbit IgG (Millipore) overnight at 4C. The immunocomplexes
were precipitated with either Protein A agarose (T-bet, H3K27ac, and
H3K4me3 ChIP) or Protein G agarose (IRF4 ChIP) beads at 4C for 2 hr,
washed, and eluted and cross-links were reversed at 65C overnight. DNA
was purified, resuspended in H2O, and analyzed by quantitative PCR ason.
s after PMA and ionomycin stimulation at day 3 after
lls was determined by ChIP (day 2 after activation).
cells.
ned by ChIP assay (day 2 after activation). Data are
-deficient polyclonal CD8+ T cells were determined
er PMA and ionomycin stimulation at day 4 after
retrovirus. IFN-g production by transduced T cells
ovember 14, 2013 ª2013 Elsevier Inc. 843
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IRF4 Sustains CD8+ T Cell Responsespreviously described (Pham et al., 2012). Primers for T-bet binding to Gzmb
and Ifng loci as well as IRF4 binding to Prdm1 locus were described previously
(Geng et al., 2010; Sciammas et al., 2006). Additional primers for IFR-4 binding
are as follows: Bim promoter forward 50-GGCTCAACTACCGCAGAGTC-30,
reverse 50-GGAGGTGGTGTGAATCCAAG-30; Cdkn2a promoter forward 50-
GACCGGTAAGTGTGTCCCG-30, reverse 50-GGATGCTCGCGCTTAAAACC-30.
The IRF4 binding sites for Bim and Cdkn2a were determined with TRANSFAC
Transcription factor binding site database.
Retroviral Transduction
CD8+ T cells were stimulated with BMDCs plus a-CD3 or indicated peptides.
At day 1 of the culture, cells were transduced with bicistronic retroviruses
through spin infection (2,500 rpm, 90 min). After transduction, cells were
analyzed daily by flow cytometry.
BrdU Incorporation
Control or Irf4DCD8 mice were infected with influenza. At day 7 p.i., BrdU
(Sigma, 1 mg/mouse) was injected through i.p. After 90 min, mice were sacri-
ficed, and lung and LN cells were collected as described (Sun et al., 2009).
Cells were surface stained with CD8 and influenza-specific tetramer (PA224)
and intracellular BrdU staining was performed as described in the manufac-
turer’s manual (BD Biosciences).
T Cell Restimulation
For BMDC stimulation, BMDCs were harvested and infected with influenza
virus at approximately 100MOI for 6 hr. Then BMDCswere counted andmixed
with total lung cells at a 1.5 to 1 ratio in the presence of Golgi-Stop (BD Biosci-
ences, 1 ml/ml) and hIL-2 (40 U/ml) for an additional 6 hr. The surface staining of
cell surface markers and intracellular staining of cytokines were performed
according to a previous report (Sun et al., 2011). For PMA and ionomycin stim-
ulation of polyclonal cells, cells were restimulated with PMA (100 ng/ml) and
ionomycin (1 mg/ml) for 4 hr in the presence of Golgi-Stop (BD Biosciences)
as described and then the surface staining of cell surfacemarkers and intracel-
lular stainingof IFN-gwereperformedaspreviouslydescribed (Sunet al., 2011).
Broncho-alveolar Lavage Cytokine Determination
BAL was obtained by flushing the airway multiple times with a single use of
600 ml sterile PBS. Cells in BAL were spun down and supernatants were
collected for ELISA analysis (Biolegend) according to the manufacturer’s
manuals.
Plaque Assay
Influenza plaque assay was performed as described before (Huprikar and Ra-
binowitz, 1980). In brief, MDCK cells were grown in 6-well plates and incubated
with series dilution of BAL for 1 hr. The plates were then overlaid with low-
melting-temperature agarose (0.6%) inMEMwith BSA and tripsin and cultured
for 3 days in 37C incubator. Plates were then fixed with formaldehyde and
virus plaques were visualized with the staining of neutral red.
Flow Cytometry Analysis
Fluorescence-conjugated FACS Abs were purchased from Biolegend, BD
Biosciences, or eBioscience. Bim and p-S6 Abs were purchased from Cell
Signaling. Bim, Bcl2, and IRF4 staining was performed with Foxp3 staining
buffer set (eBioscience). For IRF4 staining, IRF4-deficient CD8+ T cells (from
either Irf4DT or Irf4DCD8 mice, termed as Irf4/) were used as negative staining
control. Cells were acquired through FACS-Calibur or LSR II (BD Biosciences).
Data were analyzed by FlowJo software (Treestar).
Statistical Analysis
Data are mean ± SEM of values from individual mice (in vivo experiments) or
mean ± SD of values from triplicate analysis of the same sample (in vitro cell
numbers and ChIP analysis). Paired or unpaired two-tailed Student’s t test
was used. We consider p values < 0.05 as significant.
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